Oncological care organisation during COVID-19 outbreak
Ahmad Awada,
Jean-Pascal Machiels,
Sylvie Rottey,
Sabino De Placido,
Massimo Cristofanilli,
Javier Cortes,
Miguel Martin,
Marco Tagliamento,
Marc Peeters,
Mario Campone,
Concetta Elisa Onesti,
Hope S Rugo,
Daniele Generali,
Khalil Zaman,
Hans Wildiers,
Nadia Harbeck,
Vivianne Tjan-Heijnen,
Sara A Hurvitz,
Guy Berchem,
Rupert Bartsch,
Fabio Puglisi,
Volkmar Müller,
Thomas Ruhstaller,
PierFranco Conte
Affiliations
Ahmad Awada
Department of Oncology Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Jean-Pascal Machiels
Aff1 0000 0001 2294 713Xgrid.7942.8Department of Medical OncologyInstitut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain Brussels Belgium
Sylvie Rottey
Aff3 0000 0004 0626 3303grid.410566.0Drug Research Unit GhentGhent University Hospital Ghent Belgium
Sabino De Placido
Aff7 grid.4691.a000000010790385XDepartment of Molecular and Clinical Endocrinology and OncologyUniversity “Federico II” Naples Italy
Massimo Cristofanilli
Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
Javier Cortes
Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Miguel Martin
Departamento de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain
Marco Tagliamento
Department of Medical Oncology, Medical Oncology 2, University of Genova & IRCCS Ospedale Policlinico San Martino, Genova, Italy
Marc Peeters
Department of Medical Oncology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium
Mario Campone
Institut de Cancérologie de l’Ouest, Centre René Gauducheau, Saint Herblain, Pays de la Loire, France
Concetta Elisa Onesti
Department of Medical Oncology, CHU de Liège, Liege, Belgium
Hope S Rugo
Department of Medicine and Division of Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, California, USA
Daniele Generali
UO Patologia Mammaria e Ricerca Traslazionale, Breast Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy
Khalil Zaman
Oncology Department, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Hans Wildiers
Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
Nadia Harbeck
Breast Center, Dept. OB&GYN and CCLMU, Ludwig Maximilians University Hospital, Munich, Germany
Vivianne Tjan-Heijnen
Medical Oncology Department, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands
Sara A Hurvitz
Los Angeles/Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA
Guy Berchem
Hemato-Oncology Department, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
Rupert Bartsch
Department of Medicine I, Medical University of Vienna, Vienna, Austria
Fabio Puglisi
Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy
Volkmar Müller
Ginecology Department, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Thomas Ruhstaller
Medical Oncology Department, Breast Center of Eastern Switzerland, St Gallen, Switzerland
PierFranco Conte
Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy
Background COVID-19 appeared in late 2019, causing a pandemic spread. This led to a reorganisation of oncology care in order to reduce the risk of spreading infection between patients and healthcare staff. Here we analysed measures taken in major oncological units in Europe and the USA.Methods A 46-item survey was sent by email to representatives of 30 oncological centres in 12 of the most affected countries. The survey inquired about preventive measures established to reduce virus spread, patient education and processes employed for risk reduction in each oncological unit.Results Investigators from 21 centres in 10 countries answered the survey between 10 April and 6 May 2020. A triage for patients with cancer before hospital or clinic visits was conducted by 90.5% of centres before consultations, 95.2% before day care admissions and in 100% of the cases before overnight hospitalisation by means of phone calls, interactive online platforms, swab test and/or chest CT scan. Permission for caregivers to attend clinic visits was limited in many centres, with some exceptions (ie, for non-autonomous patients, in the case of a new diagnosis, when bad news was expected and for terminally ill patients). With a variable delay period, the use of personal protective equipment was unanimously mandatory, and in many centres, only targeted clinical and instrumental examinations were performed. Telemedicine was implemented in 76.2% of the centres. Separated pathways for COVID-19-positive and COVID-19-negative patients were organised, with separate inpatient units and day care areas. Self-isolation was required for COVID-19-positive or symptomatic staff, while return to work policies required a negative swab test in 76.2% of the centres.Conclusion Many pragmatic measures have been quickly implemented to deal with the health emergency linked to COVID-19, although the relative efficacy of each intervention should be further analysed in large observational studies.